Advertisement
week in cancer news
  • June 17: The Week in Cancer News

    Clinical trials rebound after COVID-19 setbacks, and early treatment leads to significant reduction in anal cancer risk among people with HIV.

    by Thomas Celona

  • A Look at Disparities Across Cancer Care

    A new AACR report tracks progress in addressing cancer health disparities and identifies work that still needs to be done.

    by Eric Fitzsimmons

  • Credit Agencies to Remove Some Medical Debt From Reports

    Changes to what medical debt is included in credit reports could give patients more time to resolve outstanding bills.

    by Karon Warren

  • June 10: The Week in Cancer News

    Patients who lose weight through bariatric surgery have a lower cancer risk, and a HER2-targeted therapy gets striking results in HER2-low breast cancer patients.

    by Kevin McLaughlin

  • June 3: The Week in Cancer News

    Contrast dye shortage delays scans for cancer, and more public assistance linked to higher survival rates for Black cancer patients.

    by Eric Fitzsimmons

  • May 27: The Week in Cancer News

    A blood test could help determine who benefits from checkpoint inhibitors in lung cancer, and the FDA approves a drug combination for certain patients with acute myeloid leukemia.

    by Marci A. Landsmann

  • May 20: The Week in Cancer News

    Esophageal cancer increases in the middle-aged, and adolescent and young adult leukemia survivors face continued mortality risk after treatment ends.

    by Eric Fitzsimmons

  • The Mental Toll of a Cancer Diagnosis

    New studies shine a light on the effects of a cancer diagnosis on mental health and suicide risk.

    by Pamela Rafalow Grossman

  • May 13: The Week in Cancer News

    First child to receive CAR T-cell therapy celebrates 10 years cancer-free, and authorization denials delay treatment for patients with Medicare Advantage.

    by Marci A. Landsmann

  • May 6: The Week in Cancer News

    Adolescents and young adult cancer survivors at higher risk for dying from a new cancer diagnosis, and FDA grants full approval to Enhertu for metastatic HER2-postive breast cancer.

    by Eric Fitzsimmons